Suven Life Sciences reveals breakthrough with Ropanicant in depression treatment

Pallavi Madhiraju- September 19, 2024 0

Suven Life Sciences Limited has made a significant advancement in the fight against depression, announcing positive results from a Phase-2a proof-of-concept study involving Ropanicant (SUVN-911). ... Read More

Suven Life Sciences announces positive results from Samelisant Phase-2 study

Pallavi Madhiraju- October 30, 2023 0

Suven Life Sciences, a pioneering biopharmaceutical company specializing in Central Nervous System (CNS) disorders, recently announced the successful completion of its Phase-2 proof-of-concept study for ... Read More

Suven Life Sciences set to begin samelisant phase 2 trial in narcolepsy

Pallavi Madhiraju- June 3, 2023 0

Suven Life Sciences has announced the successful completion of enrollment for its phase-2 proof-of-concept (PoC) clinical study to evaluate the safety and efficacy of samelisant ... Read More

Suven Life Sciences to launch phase 3 clinical trial for Masupirdine

pallavi123- August 16, 2021 0

Suven Life Sciences is set to launch a phase 3 clinical trial for its 5-HT6 antagonist SUVN-502 (Masupirdine) for the treatment of agitation and aggression ... Read More